<DOC>
	<DOC>NCT01221831</DOC>
	<brief_summary>This is an open-label, multi-centre, comparative study in young, healthy, female volunteers of reproductive age. Primary objective: - To investigate the effect of 2 dosages of estetrol combined with P1 or P2, on vaginal bleeding patterns (cycle control), in comparison with a combined oral contraceptive containing estradiol valerate and dienogest Secondary objectives: - To investigate ovulation inhibition - To investigate the effect on SHBG - To assess pregnancy rate - To evaluate subject satisfaction, dysmenorrhoea, acne, and body weight - To investigate return of menstruation after treatment - To evaluate general safety and acceptability</brief_summary>
	<brief_title>Cycle Control Assessment of a Combined Oral Contraceptive Containing Estetrol and a Progestin P1 or P2</brief_title>
	<detailed_description />
	<mesh_term>Contraceptives, Oral</mesh_term>
	<mesh_term>Dienogest</mesh_term>
	<mesh_term>Estradiol 3-benzoate</mesh_term>
	<mesh_term>Estradiol 17 beta-cypionate</mesh_term>
	<mesh_term>Estradiol valerate</mesh_term>
	<mesh_term>Contraceptive Agents</mesh_term>
	<mesh_term>Estradiol</mesh_term>
	<mesh_term>Polyestradiol phosphate</mesh_term>
	<mesh_term>Contraceptives, Oral, Combined</mesh_term>
	<criteria>Women willing to use a Combined Oral Contraceptive for 6 subsequent cycles Good physical and mental health Regular menstrual cycle (2435 days) prior to screening Body mass index between (≥) 18 and (≤) 30 kg/m2 Previous use of any hormonal contraceptive method during the last 3 months prior to randomisation (only applicable for women who are not using a hormonal contraceptive method at the time of screening) Previous use of progestogenonly contraceptive methods during the last 3 months or during the last 6 months for depot progestogen preparations or an injectable hormonal method of contraception Use of phytoestrogens No spontaneous menstruation has occurred following a delivery or abortion Breastfeeding or within 2 months after stopping breastfeeding prior to the start of study medication and no spontaneous return of menstruation Status postpartum or postabortion within a period of 2 months before screening Pregnancy during accurate hormonal contraceptive use in the past Intention to become pregnant during the study An abnormal cervical smear within one year before study start Untreated Chlamydia infection Known or suspected breast cancer or a history of breast cancer A history of (within 12 months) alcohol or drug abuse Any clinically relevant abnormality Contraindications for the contraceptive steroids used in the clinical trial Use of antihypertensive drugs or use of medications interacting with the contraceptive steroids used in the clinical trial Administration of any other investigational drug within 2 months prior to screening</criteria>
	<gender>Female</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>35 Years</maximum_age>
	<verification_date>September 2012</verification_date>
</DOC>